Icagen

Icagen, Inc. has appointed Seth Hetherington, M.D. to the position of senior vice president, clinical and regulatory affairs. Dr. Hetherington is an experienced drug development executive, with more than 25 years of experience in clinical drug development and academic medicine. Most recently, Dr. Hetherington served as vice president, clinical development and chief medical officer at Inhibitex, Inc. from 2002 to May 2006.

From 1995 to 2002, Dr. Hetherington served in positions of increasing responsibility in clinical drug development at Glaxo Wellcome and GlaxoSmithKline. During this period, he made significant contributions to several clinical development programs, including work on the currently marketed pharmaceuticals Ziagen, Trizivir and Agenerase. During this period, he also served as a faculty member at the University of North Carolina School of Medicine. Prior to joining Glaxo Wellcome, Dr. Hetherington held appointments at several academic medical centers, including the University of Tennessee, St. Jude Children’s Research Hospital in Memphis and Albany Medical College. Dr. Hetherington has published extensively in the medical and scientific literature, and is board certified in both pediatrics and pediatric infectious diseases.